Citi analyst Geoff Meacham initiated coverage of Protagonist Therapeutics (PTGX) with a Buy rating and $72 price target The firm cites the potential of rusfertide in polycythemia vera and oral IL-23 in multi-billion inflammation indications for the Buy rating. Citi acknowledges the share outperformance over past three months, but believes rusfertide’s “impressive efficacy” as demonstrated in Phase 3, including improvement in quality of life scores, suggests the drug has “strong potential” in polycythemia vera patients as despite therapeutic advancement there still remains unmet need.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics’ Rusfertide: Promising Efficacy and Financial Upside Drive Buy Recommendation
- Protagonist Therapeutics: Promising Future with Rusfertide as a Standard of Care for Polycythemia Vera
- Protagonist, Takeda announces Phase 3 VERIFY study met primary endpoint
- Protagonist Therapeutics: Strategic Partnerships and Innovative Therapies Drive Buy Rating
- Protagonist announces icotrokinra data from Phase 3 ICONIC-TOTAL study